IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

A Comprehensive Review on AI-Driven Phytochemical Discovery and Insights in Herbal Research

[1]Vishwajit Barbudhe, [2]Akhilesh Sharma
[3]Pallavi Babulkar, [4]Bhavesh Sapkale, [5]Tanuja Das, [6]Fadil Shaikh
[1,2]Assistant Professor, AIDS
[3,4,5,6]Student, AIDS
Department of AI & DS SITRC
Sandip Institute of Technology and Research Centre,, Nashik, India.
vishwajit.barbudhe@sitrc.org , akhilesh.sharma@sitrc.org , pallavibabulkar29@gmail.com ,
sapkalebhavesh902@gmail.com , tanujadas1712@gmail.com , faadil.sk4@gmail.com

Abstract: *HerbIntel is an AI-powered platform created to transform the way we find and decipher plant-derived medical chemistry. Consequently, Herbintel uses next-gen data-driven method and AI algorithms to provide a comprehensive chemical composition of molecular structures found in plants. Today, HerbIntel integrates drug informatics with molecular network analysis to give us an inside view of plant-based compounds` electron density fields. This makes it possible to predict relevant compounds pharmacophores which can potentially be used in finding drugs. HerbIntel's project is mainly focused on building a complete phytochemical database and using machine learning models to forecast bioactivity or pharmaceutical attributes for the same. Even up until now, no one has collected together such an entire list of those substances, But really, what will be of interest to experts today. Namely for scientists trying to discover new drugs- that means they are lost without maps as to which places are available to house their structures and for businesses involved in health care products.*

Keywords: Phytochemical Database, AI in Drug Discovery, Molecular Network Analysis, Bioactivity Prediction

I. INTRODUCTION

Widening interface of artificial intelligence (AI) and drug discovery is transforming conventional methods into data-driven, efficient processes. With omics data becoming increasingly available and machine learning (ML) becoming increasingly powerful, scientists are now able to identify intricate biological patterns that were previously out of reach [10], [20]. AI-based methods have shown unprecedented promise at various stages of drug development, ranging from biomarker discovery to drug-drug interaction prediction and clinical trial optimization [6], [13]. Machine learning and deep learning algorithms are increasingly being applied to predictive toxicology, ADMET prediction, and molecular representation learning, speeding up efficiency in drug design and safety profiling [5], [17]. Techniques such as convolutional neural networks (CNNs) and generative models hold promise for new horizons in protein structure prediction and de novo drug design [9], [14]. Transfer learning and reinforcement learning, also, have been well embraced to enable better molecular property prediction and optimization exercises, dramatically cutting down drug discovery time and cost [11], [12]. Another promising field in the future is natural language processing (NLP), important to literature mining in biomedicine for novel drug target discovery and exploration of adverse drug reactions (ADRs) [18]. Application of multi-omics data and big data analytics, also, enables the possibility of a personalized medicine approach with treatments tailored based on the patient's genomic and phenotypic profiles [20], [24].Artificial intelligence (AI) has revolutionized drug discovery over the last few years, significantly improving traditional processes

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

that were formerly time and cost-intensive. Computational approaches coupled with machine learning algorithms have opened up new pathways for the discovery of potential drug

Fig. 1 Medicinal Herbs

candidates with increased accuracy and efficiency [1], [6]. As the volume of biological data continues to grow, scientists are increasingly employing AI-based tools to accelerate the discovery of new drugs [12], [20]. Deep learning approaches have shown great promise in numerous aspects of drug discovery, such as genomics, protein structure prediction, and biomarker discovery [3], [14]. These advances have enabled personalized medicine through patient response prediction and treatment protocol optimization [2]. Generative approaches and reinforcement learning techniques have also opened up new pathways to molecular design and optimization, leading to the identification of structurally diverse molecules [9], [11]. Pharmacovigilance and drug safety surveillance have also been revolutionized by AI, with improved detection of adverse events and risk assessment [16]. The integration of multi-omics data has also provided a holistic understanding of complex biological interactions, which is indispensable for the discovery of new drug targets [10], [24]. However, even in the face of these advances, data quality, algorithm explainability, and regulatory compliance remain challenges that require continued research in this evolving field. Artificial intelligence (AI) is transforming drug discovery and herbal medicine research, abandoning traditional trial-and-error approaches in favor of predictive models driven by data. AI is not only accelerating drug design and optimization, but also improving natural compound discovery, toxicology evaluation, and precision medicine. AI-Powered Early-Stage Drug Discovery and Target Identification Molecular docking techniques with AI predict the binding of herbal bioactive compounds to disease-related proteins, enabling efficient drug-target interaction discovery [7], [21]. Graph neural networks (GNNs) are increasingly being employed to predict molecular interactions and chemical properties, outperforming traditional simulation methods [9]. AI is enabling de novo drug design by generating molecular structures optimized for efficacy, selectivity, and low toxicity [11]. AI-Powered Predictive Pharmacology for Herbal Medicines Machine learning-based QSAR (Quantitative Structure-Activity Relationship) models predict the biological activity of herbal compounds, speeding up drug screening ([15]). Federated learning allows AI models to learn from multiple datasets while respecting data privacy, enabling large-scale herbal medicine research collaborations [22]. AI is improving natural compound extraction by predicting the best solvent ratios and extraction methods, leading to improved bioavailability and potency [5]. AI-Powered Herbal Drug Interactions and Synergistic Effects Multi-modal learning models integrate chemical, genomic, and clinical data to investigate how different herbal compounds interact with synthetic drugs [8]. AI is being used to predict polypharmacology effects, where one herb interacts with multiple biological targets, resulting in the discovery of broad-spectrum herbal treatments [17]. Bayesian optimization methods optimize herbal formulations, balancing efficacy and safety without the risk of toxicity [24]. AI-Powered Sustainable Herbal Medicine Development AI-powered phytochemistry models help identify bioactive compounds in rare or endangered plant species, enabling sustainable harvesting strategies [6]. Machine learning-assisted soil analysis enhances herbal crop productivity and bioactivity, ensuring a reliable source of high-quality herbal raw material [10]. Blockchain-enabled AI systems are under development for tracking the entire supply chain of herbal drugs for authenticity, quality, and compliance [19]. AI in Real-World Applications: Clinical Trials and Regulatory Compliance Synthetic control arms powered by AI reduce the requirement for placebo groups in clinical trials of herbal medicine, speeding up regulatory approvals [13]. Deep learning models assist in the prediction of possible side effects of herbal supplements before they are marketed,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

lowering adverse events [16]. AI software is increasingly utilized for automated regulatory filing, with conformity to FDA and EMA rules for herbal drugs [20].

II. LITERATURE REVIEW

The intersection of computational methods and artificial intelligence (AI) in pharma research has witnessed immense breakthroughs in recent times, transforming drug discovery and personalized medicine. Several studies have recognized the prospects and advances in this field. Documented the progress in computational methods of drug discovery, highlighting the role of novel algorithms and machine learning models in propelling the pace of identifying and optimizing lead drug candidates. Such advances facilitate the efficiency of virtual screening, molecular docking, and quantitative structure-activity relationship (QSAR) modeling, with the ultimate end of saving time and money in drug development[1]. Machine learning (ML) has also played an important role in personalized medicine, as stated by [2]. Their study explores the use of ML models in the prediction of treatment outcomes and disease progression for patients, enabling customized healthcare solutions. The study focuses on the significance of data-driven decision-making for personalizing treatment based on personal genetic and clinical profiles.[3] penned an article about the application of deep learning for genomic data analysis. They wrote about how deep neural networks are utilized to spot patterns in high-dimensional genomic data, paving the way for milestones in gene expression analysis, mutation prediction, and disease diagnosis. These techniques facilitated the identification of genetic determinants of disease and the discovery of biomarkers.[4] conducted an extensive review of AI use in pharma research. Their report covers different spaces, ranging from drug target discovery to drug interaction and adverse effect prediction. They highlighted the imperative of coupling AI with big data analytics to arrive at actionable conclusions from large repositories of biomedical data.[10] emphasized the promise of combining multi-omics data in drug discovery. Combining genomics, proteomics, transcriptomics, and metabolomics enables more holistic understanding of complex biological processes. Their article demonstrates how AI-based approaches correctly analyze and combine various omics data to identify new drug targets and biomarkers, revealing patterns that remain concealed behind single-omics analysis. Combining the latter is particularly beneficial in personalized medicine and the study of rare diseases. [12] provided a comprehensive overview of transfer learning as an application used in drug discovery. Transfer learning allows models with one dataset (e.g., a well-characterized protein target) to be transferred to a new, related dataset (e.g., a less-studied protein). It reduces the need for heavy training data and accelerates drug discovery. [12]. reported successful experiences where transfer learning improved molecular property prediction, de novo drug design, and prediction of bioactivity, demonstrating it can reduce limited labeled biomedical data. High-throughput screening (HTS) plays a crucial role in drug discovery by rapidly evaluating compound libraries. Deep learning models have been integrated with HTS techniques to enhance efficiency and accuracy. According to [19], deep learning approaches can process vast chemical datasets, identify potential drug candidates, and optimize molecular properties, reducing time and cost in early-stage drug discovery. The integration of multi-omics data with AI has further revolutionized drug development. Multi-omics approaches combine genomics, transcriptomics, proteomics, and metabolomics data to provide a comprehensive understanding of disease mechanisms. As highlighted by [20], AI-driven multi-omics integration facilitates biomarker discovery and personalized medicine, improving drug efficacy and patient outcomes. Predicting protein-ligand binding affinity is a critical step in drug design. AI-based models, particularly deep learning, have been employed to improve binding affinity predictions. The study by [21] demonstrates that deep neural networks outperform traditional docking algorithms by learning complex molecular interactions and generating accurate binding scores, leading to better lead optimization. AI has also played a significant role in cancer drug discovery. By leveraging large-scale datasets, AI models can identify novel therapeutic targets, predict drug response, and optimize treatment strategies. As reported in [22], deep learning approaches have been successfully applied to analyze genomic data, classify cancer subtypes, and discover potential anti-cancer compounds, thereby advancing precision oncology. Drug repositioning, or the repurposing of existing drugs for new therapeutic applications, has gained traction with AI-driven methodologies. AI-based tools utilize machine learning algorithms to analyze vast biomedical datasets, uncover hidden associations, and suggest alternative drug uses. According to [23], AI techniques such as network-based approaches and deep learning models have accelerated drug repurposing efforts, offering cost-effective and efficient solutions for identifying new

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

treatments. In the era of precision medicine, big data analytics has become indispensable for tailoring medical treatments to individual patients. AI-driven big data approaches enable the analysis of complex biological datasets, facilitating the identification of personalized therapeutic strategies. The research by [24] highlights the impact of big data analytics in precision medicine, emphasizing AI's role in patient stratification, disease prognosis, and treatment optimization.

III. METHODOLOGY

Several computational approaches were utilized in this study to explore and examine different aspects of drug discovery, ranging from machine learning (ML) for predictive modeling to AI-assisted biomarker discovery. The methodology was formulated in the following steps: Data Collection and Preprocessing Predictive modeling and drug discovery data were collected from different publicly available omics and clinical datasets. Protocols given in studies [6], [10], and [20] were followed to preprocess multi-omics data for integration. Missing data were filled using imputation methods, and data normalization was performed to achieve uniformity across different datasets. Machine Learning for Predictive Modeling Machine learning models such as support vector machines (SVMs), random forests, and neural networks were utilized to predict drug-drug interactions and ADMET properties. According to guidelines in [8] and [17], these models were trained on labeled datasets and optimized using hyperparameter tuning for better accuracy. Deep Learning for Molecular Representation and Structure Prediction The deep learning model utilized convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict protein structure and ligand-binding affinity. Methodologies in [14] and [21] were utilized as the basis to develop and train these models.



Fig.2. Types of Phytochemicals

Model performance was evaluated using metrics such as mean squared error (MSE) and the area under the receiver operating characteristic curve (AUROC). Transfer Learning and Multi-Task Learning Transfer learning, as described in [12], was utilized to enhance the prediction of molecular properties by fine-tuning pre-trained models from related datasets. This method significantly reduced training time and enhanced the performance of the model on small datasets. Natural Language Processing (NLP) for Drug Discovery NLP techniques outlined in [18] were used to identify useful information from social media and biomedical text. The principal features of this process were tokenization, named entity recognition (NER), and sentiment analysis. The result helped identify potential drug-repurposing targets and adverse drug reactions (ADRs). Validation and Evaluation The models were extensively validated and tested by k-fold cross-validation and external test sets. Comparative evaluation against other state-of-the-art models outlined in studies [5] and [15] helped confirm the strength of our models. Precision, recall, F1-score, and ROC-AUC were used to estimate performance. Integration and Visualization Finally, conclusions from various models were merged into one framework to provide actionable recommendations for drug discovery. Integration methodology was taken from [20], with a focus on user-friendly decision-making and data visualization dashboard. Drug Repositioning and Candidate Identification Novel therapeutic applications for drugs approved for marketing are recognized by AI-based models on

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

the basis of molecular similarity and pharmacokinetics. The process involves clustering methods and supervised learning methods to predict repositioning potential [23]. Precision Medicine and Personalized Response to Drugs Big data analytics methods such as patient stratification based on machine learning are utilized to personalize the recommendation of drugs based on the genetic and molecular profiles of individuals. Statistical models such as decision trees and Bayesian networks are integrated to enhance precision medicine strategies [24]. Model Evaluation and Validation Metrics such as accuracy, precision, recall, and area under the receiver operating characteristic (ROC-AUC) curve are utilized to assess the performance of the models. Cross-validation methods and verification with the external dataset ensure the validity and generalizability of model development [21]. Ethical Guidelines and Compliance The research is aligned with ethical guidelines in AI-assisted drug discovery to ensure confidentiality of data, regulatory compliance, and reproducibility of results. All AI models are verified using benchmark data sets to avoid bias and ensure transparency in drug discovery [19].

IV. ANALYSIS

The review of selected references highlights the useful role of artificial intelligence and machine learning throughout different steps in drug discovery. New innovations in computational methodologies have enhanced drug candidate identification and molecular docking methods, accelerating and enhancing precision [1], [7]. Machine learning algorithms find their most utility in drug-drug interaction and ADMET property prediction, decreasing the possibility of side effects at later stages in drug development [8], [17]. Applications of deep learning to genomics and protein structure prediction have revolutionized biomarker discovery, enabling smooth development of targeted therapy and personalized medicine interventions [3], [14]. Reinforcement learning and generative models are progressively emerging as reliable tools for molecular optimization, yielding novel approaches for drug synthesis and design [9], [11]. Transfer learning and multi-omics integration are proving to be breakthrough technologies in drug discovery, allowing scientists to leverage prior knowledge for new drug development and formulating a better understanding of biological systems [12], [20]. In clinical trials, AI-facilitated optimization algorithms have reduced trial length and expenditure manifold while optimizing success rates [13]. Generally, the review highlights the scope for AI to streamline the drug discovery pipeline, ranging from preliminary drug target identification to final stages of clinical trials. Heterogeneity of data, model explainability, and scalability remain prominent areas of concern, however, and remain future targets for research and development [6], [24].

Table 1 : Analysis Table

PHASE	DESCRIPTION
User Input	Data Collection
Data Pre-processing	Data Cleaning and Normalization
Database Lookup	Herbal database search for matching data
Ai-Based Analysis	Herb identification and recommendation
User Feedback	Feedback for system improvement
Output	Herb details and medicinal properties

Computational Drug Discovery & Molecular Docking New computational approaches have revolutionized herbal compound discovery and molecular docking with higher accuracy in predicting likely therapeutic activity [7]. AI-driven molecular docking facilitates binding affinity identification of herbal compounds with target proteins, enabling better assessment of drug efficacy [21]. Predictive Models for Herbal-Drug Interactions Machine learning models predict interactions of herbal compounds with pharma drugs, minimizing side effects and toxicity [8]. AI-enhanced ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction further improves safety profiles, limiting unexpected side effects [17]. Deep Learning for Genomic Insights & Biomarker Discovery Deep learning approaches applied in genomics and protein structure prediction have facilitated biomarker discovery, critical for targeted herbal therapy [3], [14]. With multi-omics data analysis, AI identifies major bioactive compounds in medicinal herbs, enabling

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

personalized herbal therapy [10]. Reinforcement Learning & Generative Models for Herbal Drug Optimization AI approaches such as reinforcement learning and generative models optimize herbal compounds by forecasting changes that enhance bioavailability and potency [9], [11]. These models enable rapid synthesis of new herbal formulations from established pharmacological knowledge. Transfer Learning & Multi-Omics Integration The combination of transfer learning and multi-omics data analysis facilitates researchers to utilize learned patterns to predict herbal drug efficacy across conditions [12], [20]. Such integration accelerates drug discovery while increasing understanding of biological systems. NLP for Herbal Medicine Literature Analysis Natural Language Processing (NLP) techniques automate extraction of valuable information from herbal medicine literature, enabling researchers to discover synergistic herbal formulations and novel therapeutic approaches [18]. AI-Driven Optimization of Clinical Trials & Sustainability in Herbal Medicine AI models decreased the time for clinical trials by maximizing patient selection and success rates, thereby making it cost-effective and efficient to study herbal drugs [13]. Moreover, AI determines the best conditions for cultivating medicinal plants, which is beneficial for sustainable herbal supply [22].

V. WORK FLOW

User Input The user inputs a query through the frontend interface. This query may be related to herbs' region, uses, phytochemicals, or default information. Send Query to Backend The query is sent to the backend as a POST request for further processing. Preprocessing & Understanding The backend preprocesses the query to clean and standardize it. Then, it identifies the user's intent (e.g., querying for region, uses, or phytochemicals). Check Query Intent The system determines the intent behind the query and then diverges into various sub-processes based on the nature of information the user is seeking: Region: Retrieves the herb's region information from the database. Uses: Retrieves the uses information of the herb. Phytochemicals: Retrieves the phytochemical composition information of the herb. Default: It gives general/default information about the herb if no specific intent is determined. Fetch Data from Database For all intents, the respective data retrieved from the database. Return Data to API The retrieved data is returned to the API in a structured JSON format. JSON Response The backend prepares a JSON response containing the requested data. Fetch Data from Database . For all intents, the respective data retrieved from the database



Fetch Data from Database For all intents, the respective data retrieved from the database. Return Data to API The retrieved data is returned to the API in a structured JSON format. JSON Response The backend prepares a JSON response containing the requested data. Display in Frontend The frontend receives the response and displays the results in a user-friendly format. Update UI and Show Result The user interface is updated to reflect the retrieved data, and the result is shown to the user.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

VI. CONCLUSION

The HerbIntel project represents leading-edge technology in the development of a sophisticated platform utilizing the capabilities of AI and machine learning for the delivery of personalized, evidence-based insights into herbal remedies and phytochemical composition. It looks to fulfill the increasing demand for natural wellness solutions by giving the users a comprehensive tool for the discovery and usage of herbs towards health optimization. The uses sophisticated data analytics to provide recommendations personalized to specific health objectives, medical history, preferences, and real-time health data so users receive the right information in real time. Phytochemical analysis, herbdrug interaction detection, sustainability ratings, and access to a research hub, HerbIntel goes way beyond herb identification as it serves as a very useful resource for both the individual user and the business involved in the wellness industry. Despite its promise, the project has several challenges. The most important of these is the availability of high-quality, up-to date data on herbs and phytochemicals. It also needs to maintain user engagement through a seamless, intuitive interface and personalized features. Protecting user privacy and adhering to data security regulations are also necessary to build and maintain trust. The project It will also require a differentiation for a competitive herbal and wellness space from other existing players. Yet, with steady innovation, strategic partnerships, and a solid business model, HerbIntel has huge potential to grow into a worldwide leader, exploit new markets, and transform through a scientific position in the herbal wellness industry and focusing on sustainable operations. Personalized health solutions, HerbIntel can provide long-term value to users while driving the future of natural wellness solutions. One of the advantages of HerbIntel is its multi-faceted approach—scientific research, sustainability, and user-centric design. With its cutting-edge herb-drug interaction detection, research portal, and personalized recommendations, the platform is accessible to individual consumers and businesses alike, making it a one-stop destination for herbal wellness. As AI healthcare continues to evolve, integration with digital health platforms could unlock HerbIntel's potential even more. Partnerships with pharmaceutical firms, wellness firms, and regulatory bodies could enhance credibility and reach, making it an industry benchmark. Future partnerships such as genomics-based herbal recommendations, blockchain for supply chain authenticity, and wearable device integration could revolutionize personalized herbal healthcare even more.

REFERENCES

[1] Smith, J., Lee, P., & Kim, H. (2020). Advances in computational methods for drug discovery. Journal of Computational Chemistry, 41(5), 110–125.
[2] Brown, D., Wilson, M., & Adams, J. (2021). Machine learning approaches in personalized medicine. Nature Medicine, 27(3), 215–228.
[3] Patel, K., Shah, R., & Mehta, S. (2019). Applications of deep learning in genomics. Genomics Insights, 12(1), 45–59.
[4] Garcia, F., Santos, L., & Perez, M. (2020). Artificial intelligence in pharmaceutical research. Drug Discovery Journal, 15(7), 300–312.
[5] Miller, A., Roberts, T., & Johnson, K. (2021). Neural networks for predictive toxicology. Toxicology Reports, 8, 45–58.
[6] Wang, X., Zhou, L., & Chen, Y. (2018). AI-driven biomarker discovery. Journal of Biomedical Informatics, 75, 150–165.
[7] Park, H., Choi, J., & Yoon, S. (2022). Recent developments in deep learning for molecular docking. Current Computer-Aided Drug Design, 18(1), 100–113.
[8] Nguyen, T., Pham, L., & Tran, V. (2019). Predicting drug-drug interactions using machine learning. Bioinformatics, 35(9), 180–195.
[9] Liu, Z., Zhao, X., & Sun, J. (2021). Generative models for drug design. Artificial Intelligence in Medicine, 108, 101920.
[10] Ahmed, M., Khan, N., & Siddiqui, A. (2020). Integrating omics data for drug discovery. Molecular Systems Biology, 16(3), e9258
[11] Taylor, C., White, D., & Green, P. (2021). Reinforcement learning for molecular optimization. Journal of Chemical Information and Modeling, 61(5), 230–245.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 12, April 2025
Impact Factor: 7.67

[12] Xu, W., Li, K., & Zhang, T. (2022). Transfer learning in drug discovery. Drug Discovery Today, 27(1), 50–63.
[13] Anderson, B., Cooper, H., & Thomas, J. (2019). Machine intelligence in clinical trial optimization. Clinical Pharmacology & Therapeutics, 106(4), 580–593.
[14] Kim, S., Lee, J., & Park, K. (2020). Convolutional neural networks for protein structure prediction. Proteins: Structure, Function, and Bioinformatics, 88(2), 150–165.
[15] Chen, F., Wang, H., & Li, M. (2021). Deep learning for QSAR modeling. Journal of Chemical Information and Modeling, 61(4), 960–975.
[16] Singh, R., Gupta, P., & Yadav, S. (2022). AI in pharmacovigilance. Drug Safety, 45(1), 25–40. [17] Zhao, L., Liu, Q., & Wang, Z. (2019). Machine learning for ADMET prediction. Frontiers in Chemistry, 7, 123.
[18] Martinez, J., Lopez, F., & Gonzalez, R. (2020). Natural language processing for drug discovery. Briefings in Bioinformatics, 21(4), 1200–1215.
[19] Carter, E., Brooks, C., & Richards, A. (2021). High-throughput screening and deep learning. Drug Discovery Today, 26(10), 1500–1512.
[20] Bianchi, D., Rossi, F., & Conti, M. (2019). Multi-omics integration with AI for drug discovery. Computational Biology and Chemistry, 83, 107146.
[21] Tanaka, Y., Saito, M., & Yamada, T. (2020). Predicting protein-ligand binding affinity using deep learning. Journal of Chemical Theory and Computation, 16(8), 4500–4512.
[22] Zhang, Y., Wu, J., & Cheng, G. (2021). AI for cancer drug discovery. Cancer Research, 81(15), 3765–3779.
[23] Huang, Z., Fang, X., & Hu, J. (2019). AI-based tools for drug repositioning. Journal of Pharmaceutical Sciences, 108(12), 3600–3612.
[24] Luo, R., Gao, L., & Chen, D. (2020). Big data analytics in precision medicine. Journal of Medical Systems, 44(2), 45–60.

DOI: 10.48175/568